Catalent, Inc. (NYSE:CTLT) Given Average Recommendation of “Buy” by Analysts

Shares of Catalent, Inc. (NYSE:CTLT – Get Rating) have been assigned an average rating of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $142.88.

CTLT has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of Catalent in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft dropped their price objective on Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a research note on Tuesday, April 12th.

Catalent stock opened at $110.67 on Friday. The stock’s 50 day moving average is $100.49 and its 200 day moving average is $108.13. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.89 and a quick ratio of 2.25. The firm has a market cap of $19.83 billion, a P/E ratio of 40.10, a P/E/G ratio of 1.70 and a beta of 1.43. Catalent has a one year low of $86.34 and a one year high of $142.64.

Catalent (NYSE:CTLT – Get Rating) last released its quarterly earnings results on Tuesday, May 3rd. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. Catalent had a net margin of 10.72% and a return on equity of 15.07%. The firm had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same quarter last year, the business earned $0.78 EPS. The company’s revenue was up 20.9% compared to the same quarter last year. Equities analysts anticipate that Catalent will post 3.56 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in CTLT. Morgan Stanley raised its position in shares of Catalent by 114.0% during the second quarter. Morgan Stanley now owns 318,438 shares of the company’s stock worth $34,430,000 after purchasing an additional 169,608 shares during the period. Assetmark Inc. bought a new position in Catalent in the 3rd quarter valued at about $34,000. Caisse DE Depot ET Placement DU Quebec boosted its stake in Catalent by 13.1% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,598 shares of the company’s stock valued at $346,000 after purchasing an additional 300 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. purchased a new position in shares of Catalent during the third quarter valued at approximately $233,000. Finally, Martingale Asset Management L P boosted its holdings in Catalent by 56.6% during the 3rd quarter. Martingale Asset Management L P now owns 3,763 shares of the company’s stock worth $502,000 after acquiring an additional 1,360 shares during the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Catalent (Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

Read More